CClinicalTrials.gg
CompletedNCT05323786Updated Apr 5, 2023

Hemodynamic Effect of Topical Anesthesia During Induction in Patients Undergoing Cardiac Surgery

An interventional study of The combined topical anesthesia induction group and The routine induction group in Coronary Artery Disease, Valvular Heart Disease and Arrythmia, sponsored by Qianfoshan Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Qianfoshan Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Patients scheduled for cardiac surgery are fragile. Hemodynamic fluctuation might be associated with adverse outcomes. Therefore, it is essential to keep hemodynamics stable during and after the induction period. Previous studies have shown that topical anesthesia can provide excellent superior supraglottic and subglottic local anesthetic effects and can significantly reduce the dosage of intravenous anesthetics. Therefore, we designed this study to explore whether the combination of topical anesthesia and intravenous anesthetics could decrease the stress response of endotracheal intubation and keep hemodynamics stable during and after the induction period.

Read the detailed description

Patients scheduled for cardiac surgery are often accompanied by cardiac insufficiency. Hemodynamic fluctuation might lead to disastrous events. Therefore, it is essential to keep hemodynamics stable during and after the induction period. The routine anesthesia induction strategy for cardiac surgery is to decrease stress response during endotracheal intubation by using large doses of opioids. However, high doses of opioids often leads to persistent and recurrent hypotension in patients from the anesthesia induction period to the beginning of the surgery. Previous studies have shown that topical anesthesia can provide excellent superior supraglottic and subglottic local anesthetic effects and can significantly reduce the dosage of intravenous anesthetics. Therefore, we designed this study to explore whether the combination of topical anesthesia and intravenous anesthetics could decrease the stress response of endotracheal intubation and keep hemodynamics stable during and after the induction period.

02

Conditions studied

  • Coronary Artery Disease
  • Valvular Heart Disease
  • Arrythmia

Keywords

  • Topical anesthesia
  • Atomization inhalation
  • Cardiac surgery
  • Hemodynamics
  • Endotracheal intubation
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 955 are open to participants now.

This study's enrollment of 96 is below the median of 123 across 3,435 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Qianfoshan Hospital is the lead sponsor of 140 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients older than 18 years and younger than 75 years;
  2. Patients scheduled to accept elective cardiac surgery;
  3. Patients of New York Heart Association (NYHA) Ⅱ~Ⅲ level grade ;
  4. Patients signed the informed consent form for the clinical study.

Exclusion criteria

Exclusion Criteria:

  1. Patients cannot cooperate to topical anesthesia;
  2. Patients who had left heart assist devices other than intra-aortic balloon counterpulsation before surgery;
  3. Patients treated with Extracorporeal Membrane Oxygenation (ECMO) prior to surgery;
  4. Patients with aortic dissection;
  5. Patients with difficult airway;
  6. Patients with high sensitivity and hypersensitivity to lidocaine;
  7. Patients with atrioventricular block;
  8. Patients who have participated in other clinical studies during the last 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    The combined topical anesthesia induction group

    Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.

    Procedure: The combined topical anesthesia induction group

  • Placebo comparator
    The routine induction group

    Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.

    Procedure: The routine induction group

Interventions

  • ProcedureThe combined topical anesthesia induction group

    Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.

  • ProcedureThe routine induction group

    Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.

06

What researchers measure

Primary outcomes

  1. The area under the curve of baseline blood pressure

    The area under the curve (AUC) of blood pressure below baseline mean arterial pressure within 3 minutes to 15 minutes after endotracheal intubation

    Time frame: From 3 minutes after endotracheal intubation(T1) to 15 minutes after endotracheal intubation(T2). T1 is defined as 3 minutes after endotracheal intubation. T2 is defined as 15 minutes after endotracheal intubation. It will take up to 1hour or 2hours.

Secondary outcomes

  1. The area under the curve of baseline blood pressure

    AUC above baseline MAP (MAP-time integral) and below baseline MAP (MAP-time integral)

    Time frame: From from the beginning of the general anaesthesia induction(T1) to 3 minutes after endotracheal intubation(T2). T1 is when midazolam is administered. T2 is defined as 3 minutes after endotracheal intubation. It will take up to 1hour or 2hours.

  2. The highest and lowest values of arterial blood pressure

    The highest and lowest values of arterial blood pressure (SBP, DBP, MAP)

    Time frame: From the beginning of the general anaesthesia induction(T1) to 15 minutes after endotracheal intubation(T2). T1 is when midazolam is administered. T2 is defined as 15 minutes after endotracheal intubation. It will take up to 1hour or 2hours.

  3. The types of vasoactive drugs used.

    The types of vasoactive drugs used ,such as the use of norepinephrine and dopamine.

    Time frame: From the beginning of the general anaesthesia induction(T1) to 15 minutes after endotracheal intubation(T2). T1 is when midazolam is administered. T2 is defined as 15 minutes after endotracheal intubation. It will take up to 1hour or 2hours.

  4. The frequency of vasoactive drugs used.

    The frequency of vasoactive drugs used ,such as the use of norepinephrine and dopamine.

    Time frame: From the beginning of the general anaesthesia induction(T1) to 15 minutes after endotracheal intubation(T2). T1 is when midazolam is administered. T2 is defined as 15 minutes after endotracheal intubation. It will take up to 1hour or 2hours.

  5. The incidence of arrhythmias.

    The incidence of arrhythmias, such as atrioventricular block, atrial fibrillation, ventricular tachycardia and so on.

    Time frame: From the beginning of the general anaesthesia induction(T1) to 15 minutes after endotracheal intubation(T2). T1 is when midazolam is administered. T2 is defined as 15 minutes after endotracheal intubation. It will take up to 1hour or 2hours.

  6. cardiac systolic function:Left Ventricular Ejection Fraction (LVEF)

    Left ventricular ejection fraction,a parameter of left ventricular systolic function. left ventricular ejection fraction (LVEF) (﹪)= stroke output (SV)/ left ventricular end-diastolic volume (LEDV)×100﹪,will be evaluated before induction of anesthesia and after central venous catheterization.

    Time frame: Beginning of the general anaesthesia induction(T1) is when midazolam is administered. T2 is when central venous catheterization is finished. It will take up to 1hour or 2hours.

  7. cardiac diastolic function:E/E' (the ratio of E peak and E') or E/A :(the ratio of E peak and A peak)

    E/A ratio, one of the main parameter for evaluating diastolic function, indicated normal diastolic function when E/A \>1, and decreased diastolic function when E/A \< 1.It will be evaluated before induction of anesthesia(T1) and after central venous catheterization(T2).

    Time frame: Beginning of the general anaesthesia induction(T1) is when midazolam is administered. T2 is when central venous catheterization is finished. It will take up to 1hour or 2hours.

  8. tricuspid annular plane systolic excursion(TAPSE)

    Tricuspid annular plane systolic excursion is a reliable indicator of right ventricular systolic function.It represents the longitudinal function of the RV and it should be measured in the apical four-chamber projection using one-dimensional echocardiography (M-mode) at the peak excursion of the tricuspid annulus (expressed in millimeters) from the end of diastole to the end of systole.It will be evaluated before induction of anesthesia(T1) and after central venous catheterization(T2).

    Time frame: Beginning of the general anaesthesia induction(T1) is when midazolam is administered. T2 is when central venous catheterization is finished. It will take up to 1hour or 2hours.

  9. Respiratory variation in inferior vena cava diameter (DIVC)

    Respiratory variation in inferior vena cava diameter (DIVC) is a measure of capacity load.DIVC=(Maximum diameter of inferior vena cava - minimum diameter of inferior vena cava) ÷ maximum diameter of inferior vena cava

    Time frame: Beginning of the general anaesthesia induction(T1) is when midazolam is administered. T2 is when central venous catheterization is finished. It will take up to 1hour or 2hours.

  10. The number of patients with postoperative hoarseness.

    Hoarseness was classified as mild, moderate and severe according to the severity.

    Time frame: Three days after the surgery

  11. The number of patients with postoperative sore throat.

    Sore throats can be evaluated using the Numeric Pain Scale (NRS) pain numerical score(0-10 score, 0: no pain, 10: worst imaginable pain).

    Time frame: Three days after the surgery

07

Study locations

1 site
  • Meng-Lv
    Jinan, Shandong 250000, China
08

References and documents

Publications

  • Du W, Lv M, Chen T, Sun X, Wang J, Zhang H, Wei C, Liu Y, Qiao C, Wang Y. The effect of topical airway anesthesia on hemodynamic profiles during the induction period in patients undergoing cardiac surgery: Study protocol for a randomized controlled trial. Front Cardiovasc Med. 2022 Oct 10;9:992534. doi: 10.3389/fcvm.2022.992534. eCollection 2022. Erratum In: Front Cardiovasc Med. 2023 Mar 31;10:1190323. doi: 10.3389/fcvm.2023.1190323. PubMed 36299870 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05323786
Lead sponsor
Qianfoshan Hospital
Responsible party
Lili Cao (Professor, Qianfoshan Hospital) — Principal investigator
First posted
Apr 12, 2022
Start date
Apr 20, 2022
Primary completion
Jan 19, 2023
Completion
Jan 21, 2023
Last update
Apr 5, 2023

Study contacts

Meng Lv, doctor
principal investigator · Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion